EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Eurazeo SE (EUZOF) fair value: what the stock is really worth

As of Jul 24, 2026: fair value of Eurazeo SE $74.60, price $46.00, upside +62.2%, quality 64 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? Yes
  3. Add to watchlist

Financial Services · US · ISIN FR0000121121

ES Eurazeo SE logo Thin data Sep 24, 2026

Eurazeo SE

EUZOF · US

Clearly undervaluedStrong Fair Value upside, but quality is only moderate.

✓Fair value $74.60 · Strongly undervalued (+62.2%)
✓Quality 64/100
!Weak Growth (revenue 5y −36.3 %/yr)
!Loss-making · -97.1% net margin (FY2025)
✓Low debt · generates free cash flow
!6.3% dividend yield · Watch coverage
!Narrow moat 17/100
!Evidence only low, so the estimate is less certain
!The models disagree: range $38.42 to $134.76

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$73.47 $31.71 Fair Value $74.60 Aug 2015 Jul 2026

White line = price, green steps = our fair value per fiscal year. As of Sep 24, 2026.

How to read this chart

60‑month range $31.71 – $73.47 · fair‑value band $38.42 – $134.76 · the $46.00 price screens below the $74.60 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Sep 24, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Eurazeo SE is a private equity and venture capital firm specializing in growth capital, series C, acquisitions, leveraged buyouts, and buy-ins of a private company, and investments in upper mid-market, mid-market and listed public companies, small- and mid-cap healthcare companies, equity in the small-mid and mid-large buyout segments.

Show more

Eurazeo SE is a private equity and venture capital firm specializing in growth capital, series C, acquisitions, leveraged buyouts, and buy-ins of a private company, and investments in upper mid-market, mid-market and listed public companies, small- and mid-cap healthcare companies, equity in the small-mid and mid-large buyout segments. The firm seeks to invest in medium-sized or large companies, SMEs, high growth companies, and real estate management and investment activities. It does not have any restrictions regarding the sectors in which it invests but prefers to invest in smart cities, services, leisure and mobility, real estate, fintech, investment activities, distribution, industry, luxury, consumer goods, business services, consumer and retail brands, and health sectors. The firm seeks to invest in consumer brands with a focus on beauty, digital health, life science, tech, financial services, personal care, household care, juvenile products, apparel, wellness, accessories, home, jewellery, leisure, health, fitness, beverage, and food companies based in United States and Europe. It typically invests in companies with a differentiated concept and global growth potential. The firm identifies companies upstream, carefully selecting them primarily from sectors driven by digital transformation and focusing on changes in lifestyle and consumption (mobility, online buying, collaboration models, etc. The firm invests in large properties in need of restructuring; residential, commercial, and office development projects; and companies with real estate assets in Western Europe. It primarily invests in New York, United States, Paris, France, Italy, North America, China and other European countries. It seeks to invest between "50 million ($54.35 million) to "250 million ($271.77 million) in small mid buyout business. It seeks to invest between "25 million ($27.18 million) and"100 million ($108.71 million) in growth business. It seeks to invest between "10 million ($10.82 million) and "40 million ($43.82 million) in the

Stock analysis

Eurazeo SE (EUZOF) currently trades at $46.00, while our model-based Fair Value estimate is $74.60, implying the stock looks roughly 38.3% undervalued today.

Show more

Valuation

Bull case: the Asset-Based group reads highest at a median of $73.65 per share, and 2 of the 3 models we run sit above the $46.00 price.

Bear case: the Growth DCF group reads lowest at $31.92, and 1 of the 3 models stay below the price. Evidence for this calculation is low.

Scenario range: $38.42 (bear) to $134.76 (bull), the price of $46.00 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 64/100 (solid quality), in the Financial Services sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Eurazeo SE reported revenue of €416M in FY2025 versus €6.1B in FY2021, a compound −49.0%/yr. Reported net income was −€404M in FY2025.

Key figures

Market cap $3.0B · P/S ratio 69.1 · EPS (TTM) $−6.80 · Dividend yield 6.3% · Net margin −97.1% · Return on equity −5.9% · Return on assets (EBIT) 6.1% · Operating margin −32.4%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (medium confidence).

What moves the price

The share trades about 22% below its 52-week high and 11% above its 52-week low.

For context, the median of 10 Financial Services peers we cover trades at −15% fair-value upside, at 62%, EUZOF screens cheaper than that median.

Fair Value models

Bear $38.42 Fair Value $74.60 Bull $134.76
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
Growth DCF $40.52 $81.72 $152.92 74
Rev-Margin DCF $19.01 $31.92 $50.37 71
NCAV (Graham) $54.96 $73.65 $109.93 54
All 3 models by family
Asset-Based
NCAV (Graham) $54.96 $73.65 $109.93 54
Growth DCF
Growth DCF $40.52 $81.72 $152.92 74
Rev-Margin DCF $19.01 $31.92 $50.37 71

Open the full fair value analysis →

Notify me when EUZOF reaches fair value

Put EUZOF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 64/100

Of which business quality 66 · Market factors (momentum, volatility) 31

Profitability 1
Margins and returns on capital today
Quality Growth 50
Are margins and returns improving?
Cashflow 100
Earnings quality: real cash, not paper profit
Fin. Strength 65
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 25
Calm price path (market factor)
Momentum 23
Price trend over the last 3–12 months (market factor)
52W Momentum 52
Distance to the 52-week high (market factor)
Net Issuance 100
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 20/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+9.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−58.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−36.3%
Start year 2020 (pandemic). Over 10 years: −19.8% a year
Revenue growth 21 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.8%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
1.3% (2020) → −79.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+18.7%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+8.1%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in EUR, euro area: IMF forecast 2.2% a year to 2030, 2.6% from 2016 to 2025) that is about +16.2% a year for the price and +5.8% for the forecasts.
Forecast 2026 (sales)+8.9%
Forecast 2027 (sales)+9.3%
Projected 2028 (sales)+8.3%
Projected 2029 (sales)+7.4%
Projected 2030 (sales)+6.5%

Watch EUZOF, get fair value alerts →

Compare Eurazeo SE with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Asset Management stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Blackstone Inc BX $112.09 $52.29 −53%
KKR & Co KKR $93.18 $29.26 −69%
Brookfield Corporation BN $36.87 $13.45 −64%
Apollo Global Management, Inc APO $116.06 $197.23 +70%
State Street Corporation STT $177.78 $139.37 −22%
Ameriprise Financial, Inc AMP $494.82 $595.40 +20%
Ares Management Corporation ARES $122.01 $103.68 −15%
Northern Trust Corporation NTRS $175.73 $123.42 −30%
Raymond James Financial, Inc RJF $161.16 $317.27 +97%
Exor N.V EXO €68.10 €136.20 +100%

Explore undervalued stocks

More undervalued Financial Services stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Eurazeo SE · Fair Value
$74.60 +38%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Eurazeo SE Fair Value". https://www.fairvalue-calculator.com/stock/EUZOF

Frequently asked questions

Is Eurazeo SE (EUZOF) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $74.60 versus the last price from Jul 24, 2026 of $46.00, about +62% upside (undervalued).
What is the fair value of EUZOF?
Our model-based fair value for Eurazeo SE is $74.60 (as of Sep 24, 2026), built from audited fundamentals. Last price (from Jul 24, 2026): $46.00.
What is the quality score of EUZOF?
Eurazeo SE has a Quality Score of 64/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Eurazeo SE (EUZOF)?
Our model-based price target is the fair value of $74.60 (as of Sep 24, 2026) from 3 valuation models. Cautious scenario $38.42, optimistic scenario $134.76. It is a calculation from audited fundamentals, not an analyst target.
What is the Eurazeo SE stock forecast for 2026?
Our models put fair value at $74.60, about +62% upside versus the last price from Jul 24, 2026 of $46.00 (undervalued). Cautious scenario $38.42, optimistic scenario $134.76. The calculation is refreshed regularly with new filings.
Does Eurazeo SE pay a dividend?
Eurazeo SE currently shows a dividend yield of about 6.35% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Eurazeo SE (EUZOF)?
For today's price to be fair in a discounted-cash-flow model, Eurazeo SE would have to grow free cash flow by +18.7 % per year for five years (discount rate 10.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -36.3 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of EUZOF use?
Our models discount Eurazeo SE at 10.1 %: a base by market capitalisation (mid), damped by beta 1.16, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Eurazeo SE that is +18.7 % per year a year over ten years, using the same discount rate (10.1 %) and the same formula as our fair value.
How much growth has Eurazeo SE (EUZOF) delivered so far?
Over the past 5 years revenue at Eurazeo SE grew -36.3 % a year. The price currently implies +18.7 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Eurazeo SE (EUZOF) growing?
The median revenue growth in the sector is +9.2 % a year. That is the yardstick for the growth priced into Eurazeo SE (+18.7 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Eurazeo SE (EUZOF)?
The free-cash-flow yield on the price is 4.53 %: that much free cash flow Eurazeo SE produces per unit of market value. When it exceeds the discount rate of our models (10.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Eurazeo SE (EUZOF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Eurazeo SE it is $74.60 per share (as of Sep 24, 2026), against a price of $46.00. It is the blended result of 3 valuation models (cash flow, earnings, asset, dividend).
Is Eurazeo SE stock overvalued or undervalued in 2026?
As of Sep 24, 2026, EUZOF trades below its calculated fair value: price $46.00, fair value $74.60, a gap of about +62% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of EUZOF?
No. The price is what the market pays today ($46.00); the fair value is what the company's own numbers justify ($74.60). For Eurazeo SE the two are $28.60 per share apart. That gap is exactly why we show both numbers side by side.
How much is Eurazeo SE worth?
The market values Eurazeo SE at about $3.0B (market capitalisation, as of Sep 24, 2026). Per share that is $46.00; our models calculate a fair value of $74.60 per share.
What do the bullish and bearish scenarios say about EUZOF?
Our models span a range for Eurazeo SE: cautious scenario $38.42, base $74.60, optimistic $134.76 per share (as of Sep 24, 2026, price $46.00). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is EUZOF from its 52-week high?
Eurazeo SE trades at $46.00, about 22% below its 52-week high of $59.01 and 11% above the low of $41.38 (as of Jul 24, 2026). Distance from the high says nothing about value: that is what the fair value of $74.60 is for.
Which stocks are comparable to Eurazeo SE?
From the same area (Financial Services) we also value Blackstone Inc, KKR & Co, Brookfield Corporation, Apollo Global Management, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Eurazeo SE stock attractive at the current price?
The data as of Sep 24, 2026: price $46.00, calculated fair value $74.60 (+62%), Quality Score 64/100, from 3 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of EUZOF calculated?
We run Eurazeo SE through 3 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $74.60, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Eurazeo SE currently trades 38 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Eurazeo SE (EUZOF)?
The latest price we hold is from Jul 24, 2026 and stands at $46.00. Our model-based fair value is $74.60, about +62% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Eurazeo SE right now?
The model range is unusually wide ($38.42 to $134.76). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (64/100) at a price below fair value, the discount is the argument here, not the business quality. For a financial, book-value and earnings-based methods matter more than a cash-flow DCF, which fits banks and insurers poorly.

Key figures of Eurazeo SE

How large is the market capitalisation of Eurazeo SE (EUZOF)?
The market capitalisation of Eurazeo SE is $3.0B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Eurazeo SE (EUZOF)?
The price-to-sales ratio of Eurazeo SE is 69.1 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Eurazeo SE (EUZOF)?
Earnings per share at Eurazeo SE are $−6.80. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Eurazeo SE (EUZOF)?
The dividend yield of Eurazeo SE is 6.3%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Eurazeo SE (EUZOF)?
The net margin of Eurazeo SE is −97.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Eurazeo SE (EUZOF)?
The return on equity (ROE) of Eurazeo SE is −5.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Eurazeo SE (EUZOF)?
On an EBIT basis the return on assets of Eurazeo SE is 6.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Eurazeo SE (EUZOF)?
The operating margin of Eurazeo SE is −32.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Eurazeo SE (EUZOF)?
Revenue at Eurazeo SE is growing −39.2% versus a year earlier (3y avg −58.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Eurazeo SE (EUZOF)?
Earnings per share at Eurazeo SE are growing −95.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Eurazeo SE (EUZOF) carry?
The net debt of Eurazeo SE is €1.1B (fiscal year 2025, ≈ 9.5 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Continue in the live analysis

Fair value and trend for 35,000+ stocks, watchlist, comparison and the diversification check. You can also try 14 days of Pro there, no card.

Open the live analysis →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.